JINGXIN(SZ:002020) Zheng Quan Zhi Xing·2025-08-26 12:16Summary of Key Points Core Viewpoint - The company, Zhejiang Jingxin Pharmaceutical Co., Ltd., is utilizing part of its idle raised funds to temporarily supplement its working capital, which is expected to enhance fund efficiency and reduce financial costs [1][3]. Group 1: Fundraising Overview - In 2021, the company completed a non-public offering of 67,567,567 shares at a price of RMB 7.40 per share, raising a total of RMB 495,040,026.39 [1]. - The raised funds are designated for the construction of a digital workshop for solid preparations with a total investment of RMB 647,918,100 [2]. Group 2: Temporary Use of Idle Funds - The company plans to use up to RMB 290 million of idle funds to supplement working capital, with a usage period not exceeding 12 months, from the board's approval date until August 13, 2025 [2][3]. - This temporary use of funds is expected to save approximately RMB 2.6 million in financial costs during the period [3]. Group 3: Compliance and Approval - The decision to use idle funds has been approved by the company's board and supervisory board, adhering to necessary legal and regulatory procedures [5][6]. - The company commits to returning the funds to the special account by the end of the usage period and assures that this action will not alter the intended use of the raised funds or affect project progress [3][5].